Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2025 ,inter alia, to consider and approve 1. To consider, approve ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ishita Drugs & Industries has informed BSE that its Board of Directors will meet on Tuesday, 11 November 2025 to consider and approve the Unaudited Financial Results for the quarter ended 30 September 2025 (Q2 FY26). The agenda also includes any other matter with the Chair's permission. The trading window for designated persons has already been closed since 1 October 2025 and will reopen 48 hours after the results are announced, as per insider trading norms. No financial figures, projections or business updates have been disclosed in this intimation — it is a routine regulatory notice under SEBI LODR Regulation 29.
This is a standard pre-results intimation and is largely procedural; shareholders should watch for the actual Q2 numbers on 11 November 2025, which will be the first meaningful datapoint affecting sentiment. No immediate material impact on share price is expected from this notice alone.